CORDIS
EU research results

CORDIS

English EN

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026

Objective

Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in quality of life, many children and adults with HMs still die from these disorders or experience disabling complications. Therefore, improvement of health care of HMs is an unmet medical need. Thus, it is important to define and align standard and efficient sets of HMs outcomes to measure and evaluate HM data for clinical decisions, long term risk/benefit profile, reimbursement, value analysis, and clinical trials design. Improving outcome measures and endpoint definitions by taking into account “real-life” data and differences in cross-national healthcare practice will undoubtedly result in an optimized, sustainable and effective treatment delivery, as well as in desirable and innovative accelerated pathways for novel drug availability. All these challenges will be addressed within a pan-EU perspective by HARMONY (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY), a comprehensive public-private European consortium of excellence.

HARMONY consortium is made up of 51 partners: 44 participants from 10 European countries and 7 pharmaceutical companies from the EFPIA. HARMONY aims to assemble, assess, connect, and analyze heterogeneous HM patient derived Big Data sets to define sets of outcome indicators that can be used for decision-making by key healthcare stakeholders. The consortium will orchestrate leading experts and working cooperative groups in HMs, European study alliances, pharmaceutical market leaders, patient advocacy groups, HTA and regulatory agencies, to: (i) optimize Europe-wide data collection and create a high-quality HM data repository for further explorative studies; (ii) establish a clinical data-sharing platform that empowers clinicians, patients and policy stakeholders to improve decision-making procedures and identify appropriate treatments to patients with HMs
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON

Address

Parque Santa Clara
42002 Soria

Spain

Activity type

Research Organisations

EU Contribution

€ 7 987 853,84

Participants (52)

Sort alphabetically

Sort by EU Contribution

Expand all

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA

Spain

EU Contribution

€ 1 000 062

UNIVERSITAET ULM

Germany

EU Contribution

€ 425 000

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA

Italy

EU Contribution

€ 1 151 652,16

EUROPEAN HEMATOLOGY ASSOCIATION

Netherlands

EU Contribution

€ 831 750

STIFTUNG ELN FOUNDATION

Germany

EU Contribution

€ 400 133

GMV SOLUCIONES GLOBALES INTERNET SAU

Spain

EU Contribution

€ 1 203 548

EUROPEAN ALLIANCE FOR PERSONALISED MEDICINE ASBL

Belgium

EU Contribution

€ 125 000

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 400 000

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 146 833

UNIVERSIDAD DE NAVARRA

Spain

EU Contribution

€ 149 500

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 149 613

STICHTING VUMC

Netherlands

EU Contribution

€ 150 000

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 150 000

UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA

Italy

EU Contribution

€ 152 770

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 150 000

GROUP FOR RESEARCH ON ADULT ACUTE LYMPHOBLASTIC LEUKEMIA

France

EU Contribution

€ 150 000

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Spain

EU Contribution

€ 153 348

EUROPEAN RESEARCH INITIATIVE ON CLL EV

Germany

EU Contribution

€ 147 748

Masarykova univerzita

Czechia

EU Contribution

€ 100 000

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON

Spain

EU Contribution

€ 150 000

THE LYMPHOMA STUDY ASSOCIATION

France

EU Contribution

€ 163 100

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 158 915

BARTS AND THE LONDON NHS TRUST

United Kingdom

EU Contribution

€ 152 750

GROUPE FRANCOPHONE DES MYELODYSPLASIES

France

EU Contribution

€ 150 000

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

Germany

EU Contribution

€ 150 000

FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS

Italy

EU Contribution

€ 150 000

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 150 000

GPOH GEMEINNUTZIGE GMBH

Germany

EU Contribution

€ 151 475

OSPEDALE PEDIATRICO BAMBINO GESU

Italy

EU Contribution

€ 149 976

UNIVERSITY OF YORK

United Kingdom

EU Contribution

€ 299 926

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

Belgium

EU Contribution

€ 100 000

EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

Netherlands

EU Contribution

€ 100 100

VIB VZW

Belgium

EU Contribution

€ 149 933

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 150 000

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

France

EU Contribution

€ 150 000

GENOME RESEARCH LIMITED

United Kingdom

EU Contribution

€ 150 000

MEDISAPIENS OY

Finland

EU Contribution

€ 149 250

MLL MUNCHNER LEUKAMIELABOR GMBH

Germany

EU Contribution

€ 199 766

LEUKANET EV

Germany

EU Contribution

€ 500 000

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

United Kingdom

EU Contribution

€ 400 000

AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS

Spain

EU Contribution

€ 199 998

BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE

Germany

EU Contribution

€ 200 000

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

Spain

EU Contribution

€ 500 000

NOVARTIS PHARMA AG

Switzerland

CELGENE MANAGEMENT SARL

Switzerland

AMGEN

Belgium

JANSSEN PHARMACEUTICA NV

Belgium

Bayer Pharma AG

Germany

MENARINI RICERCHE SPA

Italy

TAKEDA DEVELOPMENT CENTRE EUROPE LTD.

United Kingdom

ABBVIE INC

United States

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 300 000

Project information

Grant agreement ID: 116026

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 42 205 587,60

  • EU contribution

    € 20 200 000

Coordinated by:

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON

Spain